GSK eases pain for Philippines’ consumers with the launch of (Paracetamol) Panadol®

GlaxoSmithKline (GSK), a global leading healthcare company and maker of Panadol^® announced the brand entry and launch of the new (paracetamol) Panadol^® with Optizorb^® in Philippines today. The world’s trusted pain reliever will be made accessible to consumers at pharmacies across the country starting next month.

“Pain is one of the greatest personal, social and economic burdens faced by people around the world,” said John Sayers, President Consumer Healthcare, Asia, Pacific and Latin America, GSK. “Panadol has helped people find pain relief across 85 countries for over 50 years and today we are pleased to bring this leading paracetamol brand to Philippines’ consumers. This is a significant milestone for GSK in line with our global commitment to help people do more, feel better and live longer.”

Panadol^® is one of the world’s leading paracetamol-based pain relievers which is sold in more than 85 countries. Last year alone, 15 billion (paracetamol) Panadol^® tablets were sold worldwide.

“The brand is testament to our customers’ trust and faith in the product which boasts an extensive scientific research breakthrough such as the Optizorb^® technology in our new Panadol^® which is the first and only paracetamol product that contains Optizorb^®,” added Sayers.

Panadol^® with Optizorb^® is the only paracetamol brand with the unique Optizorb^® disintegration system which allows the release of its medicine in as little as five minutes vs. regular paracetamol tablets. Studies conducted by GSK have proven that 75 percent of people who take Panadol with Optizorb^® caplets reach pain relieving levels of paracetamol in the bloodstream significantly faster than those taking other generic pain relieving brands.

With a greater rate of absorption, (paracetamol) Panadol® with Optizorb® delivers therapeutic concentrations to most people suffering from a variety of pain even those with common medical conditions, such as stomach problems and heart disease. 

Panadol^® with Optizorb^® also has the broad suitability associated with standard paracetamol[1].  This means that it is well tolerated and will not irritate the stomach when used as directed.

“Following a study conducted in Philippines, we found that seven out of ten Filipinos suffer from regular headaches, and over half from muscle aches and pains in the past three months. These pain sufferers have indicated fast relief of pain  is of core importance and this has encouraged us to provide a fast and effective solution like Panadol^® with Optizorb^® to alleviate this health condition,” said JeoffreyYulo, General Manager Consumer Healthcare, GSK Philippines.

(paracetamol) Panadol® with Optizorb® comes in 36 x 10s dispenser box and each 10s catch cover has an SRP of P32.00 and will be available at all leading drugstores nationwide, starting February 2014.

For more information on pain management, visit www.Panadol.com.

---

[1]Wilson CG, Clarke CP, Starkey YY, Clarke GD. Comparison of a novel fast- dissolving acetaminophen tablet formulation (FD-APAP) and standard  acetaminophen tablets using gamma scintigraphy and pharmacokinetic  studies. Drug Dev Ind Pharm. 2011;37(7):747-753.